SCHEMBL280370

SCHEMBL280370

Cc1ccc(C(=S)CN(C)c2ccncc2)s1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.38
NPC1 O15118 3/20 0.38
CHRM5 P08912 1/20 0.36
CHKA P35790 1/20 0.36
DAO P14920 1/20 0.36
NAMPT P43490 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
DUSP3 P51452 1/20 0.33
PTPN5 P54829 1/20 0.33
PTPN11 Q06124 1/20 0.33
POLB P06746 3/20 0.33
KMT2A Q03164 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
MEN1 O00255 1/20 0.31
TAS1R3 Q7RTX0 1/20 0.31
TAS1R1 Q7RTX1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279931 0.84 RAB9A (0.43) RAB9ANPC1CHRM5CHKADAO
SCHEMBL280366 0.73 RAB9A (0.44) RAB9ANPC1DAONAMPTALDH1A1
SCHEMBL280054 0.70 RAB9A (0.41) RAB9ANPC1DAONAMPTALDH1A1
SCHEMBL280057 0.69 RAB9A (0.52) RAB9ANPC1CHRM5CHKADAO
SCHEMBL27622576 0.68 CHRM5 (0.54) RAB9ANPC1CHRM5CHKAMAPT
SCHEMBL279743 0.67 NPC1 (0.41) RAB9ANPC1DAONAMPTALDH1A1
SCHEMBL3905837 0.66 CHRM5 (0.46) CHRM5CHKAALDH1A1MAPTKMT2A
Hydrochloric Acid SCHEMBL3907034 0.65 CHRM5 (0.45) CHRM5CHKAALDH1A1KMT2A
SCHEMBL27568133 0.64 CA12 (0.42) CHRM5CHKAALDH1A1MAPTKMT2A
SCHEMBL1036118 0.62 CHRM5 (0.56) RAB9ANPC1CHRM5CHKAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL RAB9A 2458/4885NPC1 3107/4885CHRM5 3012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.